Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Haemoglobin and anaemia in the SMART study.

Mocroft A, Lifson AR, Touloumi G, Neuhaus J, Fox Z, Palfreeman A, Vjecha MJ, Hodder S, De Wit S, Lundgren JD, Phillips AN; INSIGHT SMART Study Group.

Antivir Ther. 2011;16(3):329-37. doi: 10.3851/IMP1746.

2.

Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group.

Mocroft A, Kirk O, Barton SE, Dietrich M, Proenca R, Colebunders R, Pradier C, dArminio Monforte A, Ledergerber B, Lundgren JD.

AIDS. 1999 May 28;13(8):943-50.

PMID:
10371175
3.

Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial.

Ssali F, Stöhr W, Munderi P, Reid A, Walker AS, Gibb DM, Mugyenyi P, Kityo C, Grosskurth H, Hakim J, Byakwaga H, Katabira E, Darbyshire JH, Gilks CF; DART Trial Team.

Antivir Ther. 2006;11(6):741-9.

PMID:
17310818
4.

Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.

Holkmann Olsen C, Mocroft A, Kirk O, Vella S, Blaxhult A, Clumeck N, Fisher M, Katlama C, Phillips AN, Lundgren JD; EuroSIDA study group.

HIV Med. 2007 Mar;8(2):96-104.

5.

Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial.

Phillips AN, Carr A, Neuhaus J, Visnegarwala F, Prineas R, Burman WJ, Williams I, Drummond F, Duprez D, Belloso WH, Goebel FD, Grund B, Hatzakis A, Vera J, Lundgren JD.

Antivir Ther. 2008;13(2):177-87.

PMID:
18505169
6.

Anaemia is associated with monocyte activation in HIV-infected adults on antiretroviral therapy.

Lipshultz HM, Hileman CO, Ahuja S, Funderburg NT, McComsey GA.

Antivir Ther. 2015;20(5):521-7. doi: 10.3851/IMP2940. Epub 2015 Feb 10.

7.

Incidence and predictors of recovery from anaemia within an HIV-infected South African Cohort, 2004-2010.

Ndlovu Z, Chirwa T, Takuva S.

Pan Afr Med J. 2014 Oct 1;19:114. doi: 10.11604/pamj.2014.19.114.3600. eCollection 2014.

8.

Short-term risk of anaemia following initiation of combination antiretroviral treatment in HIV-infected patients in countries in sub-Saharan Africa, Asia-Pacific, and central and South America.

Zhou J, Jaquet A, Bissagnene E, Musick B, Wools-Kaloustian K, Maxwell N, Boulle A, Wehbe F, Masys D, Iriondo-Perez J, Hemingway-Foday J, Law M; Western Africa, Eastern Africa, Southern Africa, Caribbean and Central and South America, and Asia Pacific Regions of the International Epidemiologic Databases to Evaluate AIDS-IeDEA.

J Int AIDS Soc. 2012 Jan 30;15(1):5. doi: 10.1186/1758-2652-15-5.

9.

Postpartum discontinuation of antiretroviral therapy and risk of maternal AIDS-defining events, non-AIDS-defining events, and mortality among a cohort of HIV-1-infected women in the United States.

Melekhin VV, Shepherd BE, Jenkins CA, Stinnette SE, Rebeiro PF, Bebawy SS, Rasbach DA, Hulgan T, Sterling TR.

AIDS Patient Care STDS. 2010 May;24(5):279-86. doi: 10.1089/apc.2009.0283.

10.

The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and without complete viral suppression.

Mocroft A, Bannister WP, Kirk O, Kowalska JD, Reiss P, D'Arminio-Monforte A, Gatell J, Fisher M, Trocha H, Rakhmanova A, Lundgren JD; EuroSIDA Study in EuroCOORD.

Antivir Ther. 2012;17(7):1291-300. doi: 10.3851/IMP2407. Epub 2012 Sep 26.

PMID:
23013779
11.

Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.

Imaz A, Olmo M, Peñaranda M, Gutiérrez F, Romeu J, Larrousse M, Domingo P, Oteo JA, Curto J, Vilallonga C, Masiá M, López-Aldeguer J, Iribarren JA, Podzamczer D; STOPAR study team.

Antivir Ther. 2013;18(1):125-30. doi: 10.3851/IMP2249. Epub 2012 Jul 18.

PMID:
22805174
12.

Risk of cancers during interrupted antiretroviral therapy in the SMART study.

Silverberg MJ, Neuhaus J, Bower M, Gey D, Hatzakis A, Henry K, Hidalgo J, Lourtau L, Neaton JD, Tambussi G, Abrams DI.

AIDS. 2007 Sep 12;21(14):1957-63.

PMID:
17721103
13.

Poor CD4 recovery and risk of subsequent progression to AIDS or death despite viral suppression in a South African cohort.

Takuva S, Maskew M, Brennan AT, Long L, Sanne I, Fox MP.

J Int AIDS Soc. 2014 Mar 3;17:18651. doi: 10.7448/IAS.17.1.18651. eCollection 2014.

14.

Clinical significance of transient HIV type-1 viraemia and treatment interruptions during suppressive antiretroviral treatment.

Zhang S, van Sighem A, Gras L, Reiss P, Smit C, Kroon F, Jurriaans S, Prins J, Lange J, de Wolf F.

Antivir Ther. 2010;15(4):555-62. doi: 10.3851/IMP1564.

PMID:
20587848
15.

High incidence of zidovudine induced anaemia in HIV infected patients in eastern India.

Agarwal D, Chakravarty J, Chaube L, Rai M, Agrawal NR, Sundar S.

Indian J Med Res. 2010 Oct;132:386-9.

17.

Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up.

Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund B, Neaton JD, Neuhaus J, Phillips AN.

J Infect Dis. 2008 Apr 15;197(8):1145-55. doi: 10.1086/529523.

PMID:
18476293
18.

Incidence of anaemia among HIV-infected patients treated with highly active antiretroviral therapy.

Curkendall SM, Richardson JT, Emons MF, Fisher AE, Everhard F.

HIV Med. 2007 Nov;8(8):483-90.

20.

Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.

Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, Girard PM, Grund B, Law M, Losso MH, Palfreeman A, Wood R.

J Infect Dis. 2008 Apr 15;197(8):1133-44. doi: 10.1086/586713.

PMID:
18476292

Supplemental Content

Support Center